Business Wire

MSCI Completes Private Offering of $500 Million 4.000% Senior Notes Due 2029

Share

MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today that it has successfully completed its private offering of $500.0 million aggregate amount of its 4.000% senior unsecured notes (the “Notes”) due 2029 (the “Offering”). The Notes constitute a further issuance of, are fully fungible with, rank equally with and form a single series with the $500.0 million aggregate principal amount of the 4.000% senior unsecured notes due 2029 issued on November 7, 2019. The Notes will mature on November 15, 2029.

MSCI intends to use the net proceeds from the Offering, together with available cash, for the pre-maturity redemption or repurchase of $500.0 million aggregate principal amount of its 5.250% senior unsecured notes due 2024 (the “2024 Notes”) pursuant to the indenture governing the 2024 Notes (the “Redemption”). There is currently $800.0 million aggregate principal amount outstanding on the 2024 Notes.

MSCI expects to recognize additional expenses associated with this Redemption of the 2024 Notes and exclude such amounts from the calculation of adjusted earnings per share for the fourth quarter and full-year ending December 31, 2019.

The Notes were offered only to (i) persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and (ii) certain non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act. The Notes have not been registered under the Securities Act or any state securities laws and therefore may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

About MSCI Inc.

MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 45 years of expertise in research, data and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to future events or to future financial performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond MSCI’s control and that could materially affect actual results, levels of activity, performance or achievements.

Other factors that could materially affect actual results, levels of activity, performance or achievements can be found in MSCI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed with the Securities and Exchange Commission (“SEC”) on February 22, 2019 and in quarterly reports on Form 10-Q and current reports on Form 8-K filed or furnished with the SEC. If any of these risks or uncertainties materialize, or if MSCI’s underlying assumptions prove to be incorrect, actual results may vary significantly from what MSCI projected. Any forward-looking statement in this press release reflects MSCI’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MSCI’s operations, results of operations, growth strategy and liquidity. MSCI assumes no obligation to publicly update or revise these forward-looking statements for any reason, whether as a result of new information, future events, or otherwise, except as required by law.

Contact information

Investor Inquiries
sallilyn.schwartz@msci.com
Salli Schwartz +1 212 804 5306

Media Inquiries
PR@msci.com
Sam Wang +1 212 804 5244
Melanie Blanco +1 212 981 1049
Laura Hudson +44 20 7336 9653
Rachel Lai +852 2844 9315

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online Event1.10.2020 11:08:00 EESTPress release

On Wednesday, September 30, 2020, Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading Israeli regenerative medicine company developing a platform of novel biological products, and the Abu Dhabi Stem Cells Center (ADSCC) unveiled their first joint projects in a presentation at the Malta Conferences Foundation (MCF), a global conference supported by kENUP Foundation, a promoter of research-based innovation with public and societal benefit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005476/en/ Malta Conferences address shared desire to improve quality of life and political stability in Middle East through scientific collaboration (Graphic: Business Wire) Pluristem and ADSCC presented new projects, part of the recently signed Memorandum of Understanding aimed at harnessing the power of regenerative medicine. The first joint project brings together the expertise of Pluristem and ADSCC to advance a potential

Allegro DVT Extends Leadership in 8K Video Decoding IP1.10.2020 11:00:00 EESTPress release

Allegro DVT, the leading provider of video semiconductor IP and video compliance streams, today announced the release of its AL-D3x0 family of multi-format 8K60 video decoder IPs. This complete family of multi-format video decoder IP cores enables customers to support video decoding at rates of up to 8K60 and beyond in a compact implementation optimized to a wide range of end market applications. As video applications shift from 4K to 8K, the industry needs power and cost efficient decoding cores to enable rapid rollout of new generation of devices and solutions capable of supporting such super high resolutions. With the AL-D3x0 family of products, Allegro is able to address this growing demand by providing highly configurable decoding IP core supporting a variety of selectable codecs such as JPEG, H.264, HEVC, VP9 and AV1. Furthermore, Allegro DVT’s unique and scalable architecture approach offers the best trade-off between silicon size and power consumption and keeps the operating fr

Avanti Acquisition Corp. Announces Launch of $500,000,000 Initial Public Offering1.10.2020 10:00:00 EESTPress release

Avanti Acquisition Corp. (the “Company”), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, today announced the commencement of its initial public offering of 50,000,000 units at a price of $10.00 per unit. The Company is sponsored by Avanti Acquisition SCSp, an affiliate of NNS Group, the private family office of Nassef Sawiris and Sienna Capital, a subsidiary of Groupe Bruxelles Lambert. The Company intends to be sector agnostic and to focus on European family owned or founder led businesses with a US nexus. The units are expected to be listed on the New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “AVAN.U”. Each unit consists of one share of Class A common stock and one-half of one redeemable warrant. Each whole warrant may be exercised for one share of Class A common stock at a price of $11.50 per share. Only

Castles Technology Announces the Acquisition of Spire Payments1.10.2020 08:59:00 EESTPress release

Castles Technology, one of the top global payment solutions providers which offers services to more than 50 countries around the globe, today announced completion of the acquisition of the business and assets of Spire Payments, the leading European based EFTPOS terminal solutions provider. With the acquisition of the business and assets of Spire Payments, Castles Technology is now even better positioned to deliver market-leading payment solutions that simplify and enhance merchants’ businesses, from in-store acceptance services to value-added solutions. Jean-Philippe Niedergang, Group CCO Castles Technology, says: “I am delighted to welcome Spire Payments’ customers and new colleagues to the Castles Technology family. This acquisition represents an important strategic move for the future of our businesses, as we continue to evolve and innovate to provide merchants acquirers with future-forward payments solutions.” “This acquisition delivers a perfect match between the two companies, wi

BIOCORP Announces Partnership with AARDEX Group to Extend Smart Solutions for Precision Medication Adherence1.10.2020 08:30:00 EESTPress release

Regulatory News: BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the design, development and manufacture of innovative medical devices, today announced an alliance with Belgium-based AARDEX Group, the world leader in medication adherence solutions. This alliance is to combine BIOCORP’s connected add-on solutions for drug delivery devices with AARDEX’s proprietary Medication Event Monitoring System (MEMS®) and offer a comprehensive solution to patients and healthcare providers to effectively measure and manage medication adherence. The financial terms of the agreement have not been disclosed, however the first initiative will be to integrate BIOCORP’s Injay connected solution for Pre-filled syringes (PFS) to AARDEX’s MEMS Adherence Software (MEMS AS®), to target medicines delivered by PFS with potential applications in the field of Rheumatoid Arthritis, Multiple Sclerosis, Ophthalmology, Psoriasis or Cardiovascular diseases. The roadmap a

JEOL Strengthens European Business in the Medical Equipment Segment1.10.2020 03:30:00 EESTPress release

JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) has opened a new facility in JEOL (EUROPE) B.V. (Zaventem, Belgium) on October 1, 2020, aiming to strengthen the Medical Equipment business in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930006021/en/ Demo site JEOL (EUROPE) B.V. (Photo: Business Wire) This foundation, with three instruments in operation, not only offers customers the possibility of practical demonstrations and intensive service / application training, but also enables high-quality service and fast logistics from the dedicated warehouse. This new approach is based on a long-term plan that whilst keeping pace with a high standard and matured medical environment in Europe, we will also cover emerging regions such as the Middle East, Eastern Europe and Russia, where the expected growth in economy and population can lead to a steady demand for medical infrastructure. We will continue to promote over

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom